Eli Lilly and Company (NYSE:LLY) Shares Purchased by MML Investors Services LLC

MML Investors Services LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 127,018 shares of the company's stock after buying an additional 4,657 shares during the period. MML Investors Services LLC's holdings in Eli Lilly and Company were worth $98,058,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. MetLife Investment Management LLC increased its position in Eli Lilly and Company by 0.9% during the 4th quarter. MetLife Investment Management LLC now owns 244,080 shares of the company's stock valued at $188,430,000 after buying an additional 2,280 shares in the last quarter. NWK Group Inc. increased its holdings in shares of Eli Lilly and Company by 0.9% during the fourth quarter. NWK Group Inc. now owns 15,938 shares of the company's stock valued at $12,304,000 after acquiring an additional 138 shares in the last quarter. Norinchukin Bank The raised its position in shares of Eli Lilly and Company by 7.2% in the 4th quarter. Norinchukin Bank The now owns 34,048 shares of the company's stock valued at $26,285,000 after purchasing an additional 2,280 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Eli Lilly and Company by 27.5% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 127,068 shares of the company's stock valued at $98,096,000 after purchasing an additional 27,412 shares during the last quarter. Finally, Capital International Inc. CA boosted its stake in Eli Lilly and Company by 19.1% in the 4th quarter. Capital International Inc. CA now owns 147,027 shares of the company's stock worth $113,505,000 after purchasing an additional 23,605 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on LLY shares. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Guggenheim reduced their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday. They issued an "overweight" rating and a $975.00 price objective on the stock. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,017.00.

Eli Lilly and Company Price Performance

LLY stock traded up $28.51 during midday trading on Thursday, reaching $857.93. The stock had a trading volume of 1,467,734 shares, compared to its average volume of 3,425,226. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company's fifty day simple moving average is $826.81 and its 200 day simple moving average is $819.07. The company has a market cap of $813.47 billion, a price-to-earnings ratio of 73.07, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.